EUVIMEDEUVIMED entdecken
Crossref

Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutation

Quratul Ain, Rachel L O'Connell, Parinita Swarnkar, Terri McVeigh, Angela George, Marios K Tasoulis, Gerald Ph Gui, Jennifer Wiggins, Aadil A Khan, Katherine Dc Krupa, Peter A Barry, Susana Banerjee und 1 weitere

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2024.109380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Quratul Ain und 12 weiteren Autor:innen. Beteiligte Einrichtung: Breast Surgery Unit, The Royal Marsden NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Germ-Line Mutation, Breast Neoplasms, BRCA1 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Institute for Health and Care Research, Institute of Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Women with ovarian cancer (OC) and a pathogenic variant in the BRCA1 or BRCA2 genes are at increased risk of developing breast cancer (BC). Evidence for long term outcomes in these patients who undergo bilateral risk reduction mastectomy (RRM) after ovarian cancer is sparse. The aim of this study was to analyse the long-term breast cancer-related outcomes of patients who have been diagnosed with ovarian cancer and found to have BRCA1 or 2 pathogenic variants. METHODS: Local approval was granted. The hospital clinical genetics database was interrogated to identify women who have been diagnosed with OC and a germline BRCA1/2 pathogenic variant between January 2010-March 2020. Patient demographics, OC treatment as well as any BC related information was analysed. RESULTS: 148 women were diagnosed with OC and a pathogenic variant in BRCA1/2 in the study period. 47 patients were excluded as they did not have treatment at our institution. 101 patients were included. The median age at diagnosis of OC was 52 years (IQR 46-61). Eighty-four (82 %) were FIGO stage 3 or 4 OC. At a median follow-up of 63 months (IQR 39-94), 55 (54.4 %) women had been diagnosed with a recurrence of ovarian cancer and 38 (37 %) women have died. Twenty-one (21 %) women were diagnosed with BC. 13 (12.9 %) had BC before OC, 4 after and 4 synchronous with OC. Of the remaining patients who did not have BC, 6 underwent bilateral risk reduction mastectomy (RRM) after treatment for OC. DISCUSSION: Risk of disease recurrence and death due to stage 3 and 4 ovarian cancer remained high in this time period. RRM can be undertaken in carefully selected patients, however we would recommend reserving this for women who have favourable OC disease prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsGerm-Line MutationBreast NeoplasmsBRCA1 ProteinBRCA2 ProteinHumansFemaleMiddle AgedMastectomyRetrospective StudiesNeoplasm Staging

Substanzen

BRCA1 ProteinBRCA2 ProteinBRCA1 protein, humanBRCA2 protein, human

Autor:innen und Institutionen

  • Breast Surgery Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Breast Surgery Unit, The Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK.
  • Genetics Department, The Royal Marsden NHS Foundation Trust, London, UK.
  • Genetics Department, The Royal Marsden NHS Foundation Trust, London, UK; Medical Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Institute of Cancer Research, London, UK; Plastic Surgery Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Institute of Cancer Research, London, UK; Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Förderung

  • National Institute for Health and Care Research
  • Institute of Cancer Research

Zitieren

APA

Ain, Q., O'Connell, R. L., Swarnkar, P., McVeigh, T., George, A., Tasoulis, M. K., Gui, G. P., Wiggins, J., Khan, A. A., Krupa, K. D., Barry, P. A., Banerjee, S., & Rusby, J. E. (2025). Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutation. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2024.109380

Vancouver

Ain Q, O'Connell RL, Swarnkar P, McVeigh T, George A, Tasoulis MK, et al. Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutation. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2024.109380

BibTeX
@article{Ain2025,
  author = {Ain, Quratul and O'Connell, Rachel L and Swarnkar, Parinita and McVeigh, Terri and George, Angela and Tasoulis, Marios K and Gui, Gerald Ph and Wiggins, Jennifer and Khan, Aadil A and Krupa, Katherine Dc and Barry, Peter A and Banerjee, Susana and Rusby, Jennifer E},
  title = {Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutation},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2024.109380}
}
Kostenlos starten →